Neural circuit mechanisms of the cholecystokinin (CCK) neuropeptide system in addiction

Yihe Ma, William J. Giardino

Department of Psychiatry & Behavioral Sciences and Wu Tsai Neurosciences Institute, Stanford University School of Medicine, Stanford, CA, USA

Abstract

Given historical focus on the roles for cholecystokinin (CCK) as a peripheral hormone controlling gastrointestinal processes and a brainstem peptide regulating food intake, the study of CCK as a limbic neuromodulator coordinating reward-seeking and emotional behavior remains underappreciated. Furthermore, localization of CCK to specialized interneurons throughout the hippocampus and cortex relegated CCK to being examined primarily as a static cell type marker rather than a dynamic functional neuromodulator. Yet, over three decades of literature have been generated by efforts to delineate the central mechanisms of addiction-related behaviors mediated by the CCK system across the striatum, amygdala, hypothalamus, and midbrain. Here, we cover fundamental findings that implicate CCK neuron activity and CCK receptor signaling in modulating drug intake and drug-seeking (focusing on psychostimulants, opioids, and alcohol). In doing so, we highlight the few studies that indicate sex differences in CCK expression and corresponding drug effects, emphasizing the importance of examining hormonal influences and sex as a biological variable in translating basic science discoveries to effective treatments for substance use disorders in human patients. Finally, we point toward understudied subcortical sources of endogenous CCK and describe how continued neurotechnology advancements can be leveraged to modernize understanding of the neural circuit mechanisms underlying CCK release and signaling in addiction-relevant behaviors.

Keywords

Cholecystokinin; Neuropeptide; Circuit; Addiction; Alcohol; Reward

Introduction

Cholecystokinin (CCK) is the most abundant neuropeptide, widely distributed in the brain and central nervous system [51]. CCK is also localized to peripheral sites including the extraintestinal endocrine cells and cardiomyocytes. First discovered in the gastrointestinal system, the role of CCK in digestion has been well-explored. However, the exact role of...
CCK in the central nervous system remains elusive. There has been a continued interest to decipher how CCK-expressing interneurons contribute to hippocampal and cortical circuits [44], however most studies examined CCK solely as a molecular marker rather than a functional peptide modulator [37]. In addition, beyond the cortex and hippocampus, dense clusters of CCK neurons exist throughout the amygdala, hypothalamus, mesolimbic dopamine (DA) system, and periaqueductal midbrain cell groups [5, 21, 34], indicating a broad diversity of mechanisms for CCK neuromodulation of emotional states (see Fig. 1). The organization of CCK-releasing pathways in the brain remains understudied and largely relies on historical reports using classical lesion methods that pointed mostly toward ipsilateral long-range projections. For example, Zaborsky et al. and You et al. used radioimmunoassay and microdialysis to identify partial reductions of CCK protein levels in downstream forebrain target areas of the striatum and pallidum following either transection of the medial forebrain bundle, destruction of the piriform cortex, widespread cortical lesion, or 6-hydroxydopamine lesion of the ventral tegmental area (VTA) [80, 82]. These data indicate that extracellular CCK content in the nucleus accumbens (NAcc), ventral pallidum (VP), and bed nucleus of the stria terminalis (BNST) originates from the cortex and mesolimbic DA system, but also from additional unidentified central sources.

Like many other neuropeptides, CCK co-localizes and interacts with other neurotransmitters and neuromodulators, such as DA, gamma-aminobutyric acid (GABA), serotonin (5HT), and endogenous opioid peptides [51]. It is possible that CCK serves as an intercellular messenger peptide locally and/or distally to represent internal physiological state and emotional state. Indeed, activation of CCK receptors has been shown to modulate the mesolimbic reward system, anxiety, and satiety [2]. These behavioral effects of CCK suggested its role in the neurobiological processes underlying addiction, and over the past 30 years, several studies directly tested the link between CCK and phenotypes relevant to the etiology of substance use disorders. However, many of these experiments relied solely on pharmacological methods and were performed nearly exclusively in male rats, limiting understanding of potential sex differences and circuit mechanisms in addiction-relevant CCK function. Recent advances in neurotechnology now allow detailed examination of CCK neuronal pathways and peptide signaling with unprecedented resolution, standing to substantially revise the framework for understanding CCK functions in reward-seeking behaviors. In this review, we summarize the evidence that supports the role of CCK in behaviors related to addiction to psychostimulants, opioids, and alcohol, shedding light on future studies on CCK and potential therapeutic strategies for substance use disorders.

Molecular characterization of CCK

Biogenesis and degradation of CCK has been reviewed in [4, 11, 59]. CCK is synthesized and released in various molecular forms across species, with different cellular localization and affinity to receptors. Only one CCK mRNA has been identified, which codes for the 115 amino acids product preproCCK. Bioactive CCK peptides are derived from a 58 amino acid sequence. The C-terminal pentapeptide amide of CCK is critical for biological effects, and is also conserved across other homologous peptides such as gastrin. Neurons mainly release the C-terminal octapeptide CCK-8 and also CCK-5. Sulfation of the tyrosyl...
residue in position seven determines CCK’s receptor affinity. The sulfated CCK octapeptide (CCK-8S) is widely distributed in the central nervous system; however, the mesencephalon may contain substantial amounts of unsulfated CCK-8 [6]. Degradation of CCK may involve membrane-bound aminopeptidases, a membrane-bound isoform of tripeptidyl peptidase, and neprilysin (enkephalinase), a membrane-bound metalloendopeptidase that also inactivates other peptides such as enkephalin and angiotensin [15, 60, 84].

**CCK receptors**

CCK peptides act through two G-protein coupled receptor subtypes, CCK-A (CCK1) receptor, and CCK-B (CCK2) receptor, encoded by the genes Cckar and Cckbr, respectively. CCK1 receptor is highly expressed in the gastrointestinal tract, binding to CCK-8S with high affinity. CCK2 receptor is the primary subtype in the brain and also in the stomach, binding to non-sulfated and sulfated CCK-8, gastrins, and C-terminus fragments such as CCK-5. Although expressed at lower levels than CCK2R, CCK1R in the central and peripheral system mediates satiation signals and other behaviors, previously reviewed in detail [2]. It is worth noting that like some other GPCRs, CCK1R and CCK2R are capable of coupling with multiple G-protein subtypes. CCK1R predominately couples with Gq, but also Gs, Gi, and G13; CCK2R functions through Gq and also Gi signaling [45, 83].

Regarding presynaptic vs. postsynaptic expression patterns of CCK receptors, little is known within the classical addiction neurocircuits. CCK1R appears to be located presynaptically on habenular inputs to the interpeduncular nucleus [33], as well as in the parabrachial nucleus and area postrema where it presynaptically modulates excitatory transmission [65, 68]. Other reports identified a postsynaptic effect of CCK2R in layer 6b cortical neurons [10] and presynaptic actions of CCK2R in the hippocampus to facilitate glutamate release [4, 7, 14].

**CCK and psychostimulants**

Discovery of abundant CCK co-localization with DA in neurons of the midbrain tegmentum initiated strong interest in studying the CCK system in DA-dependent effects of psychostimulant drugs of abuse, particularly with regard to midbrain DA projections to the ventral striatum, reviewed previously in detail [72] and summarized in Table 1. For example, amphetamine and methamphetamine administration increased CCK messenger ribonucleic acid (mRNA) levels throughout the mesolimbic DA pathway, though these effects may be particularly time-sensitive [36, 49]. Early findings also suggested an inverse relationship between levels of ventral midbrain CCK expression and DA neuron activity associated with locomotor activity and drug self-administration [48]. In line with these data, CCK2R pharmacological blockade or CCK1R genetic knockout in rats led to elevated baseline DA levels in the striatum and potentiated striatal DA release in response to cocaine or amphetamine administration [19, 46].

However, Vaccarino proposed that CCK could have both DA-enhancing and DA-limiting effects in the ventral striatum based on the degree of CCK release, presynaptic vs. postsynaptic locations of CCK1R vs. CCK2R, and the rostral-caudal sites of CCK activation in the nucleus accumbens (NAcc) [72]. Indeed, CCK1R receptor
blockade, either systemically or directly in the NAcc, decreased amphetamine-induced locomotor sensitization [16, 79], opposite to earlier findings with a CCK2 receptor antagonist [32]. Furthermore, intra-NAcc CCK2R agonist administration increased the progressive ratio breakpoint in amphetamine self-administration experiments, suggesting that NAcc CCK2R signaling has anti-reward effects [8]. These results are analogous to findings that intracerebroventricular (i.c.v.) administration of the CCK-8 peptide blocked methamphetamine-induced acute locomotor stimulation and progressive sensitization [26].

In a model of stress-induced reinstatement of cocaine-seeking behavior, Liu et al. found a protective effect of CCK2 receptor blockade [47], consistent with the suggestion by some that CCK2 receptor antagonists may have utility in treating cocaine addiction [13, 18]. Yet, we emphasize that nearly all the above studies were conducted in male rats. More recent findings that estradiol (E2) interacts with cocaine exposure to increase CCK protein levels in the ventral tegmental area (VTA) of ovariectomized female mice [54] suggest a critical examination of sex differences and hormonal influences on CCK’s role in responding to psychostimulant drugs.

**CCK and opioids**

Based on literature implicating the CCK system in regulation of pain and anxiety, Hebb et al. hypothesized “anti-opioid” functions of CCK action throughout mesolimbic circuits [28]. Consistent with this idea, evidence from genetic knockout mice showed that loss of the CCK2 receptor resulted in upregulation of central endogenous opioid peptides [55]. Furthermore, Noble et al. [53] identified a relationship between higher expression of CCK/CCK receptor signaling and greater sensitivity of a CCK2R antagonist to promote opioid reward [53]. Behavioral effects and molecular changes resulting from altering CCK signaling activity in animal models of opioid abuse are summarized in Table 2.

While effects of CCK system manipulations on intravenous opioid self-administration were mixed [29], the reward-seeking model of conditioned place preference (CPP) demonstrated opposite actions of CCK1R and CCK2R antagonists in blocking and potentiating the acquisition of morphine CPP, respectively [30,31]. I.c.v. administration of the CCK-8 peptide blocked the acquisition and potentiated the expression of morphine-induced CPP, consistent with proposed anti-opioid effects of CCK [74]. However, in contrast to data supporting the anti-opioid hypothesis, experiments on aversive effects of opioid withdrawal indicated that CCK can have pro-opioid actions as well. For example, CCK-8 acted in a CCK1R-dependent manner to attenuate conditioned place aversion (CPA) and anxiety-like behavior resulting from naloxone-induced precipitation of morphine withdrawal [75, 81], and CCK restored morphine-induced disruption of hippocampal LTP [76].

Once more, it should be noted that the above studies were conducted nearly exclusively in male subjects. Data from ovariectomized female rats found that the opioid antagonist naltrexone potentiated E2-induced increases in CCK mRNA within the bed nucleus of stria terminalis (BNST) of the extended amygdala, indicating the potential for major sex differences and hormonal influences on opioid-CCK interactions in limbic circuits [17, 50].
CCK and alcohol

Given the unique caloric properties of ethanol, previous hypotheses highlighted the overlap in neuropeptide pathways that regulate both alcohol drinking as well as feeding, including CCK [70]. While i.p. injections of CCK decreased alcohol intake in rats, this was proposed to act through a peripheral mechanism, consistent with the well-documented role of brainstem and peripheral CCK actions in mediating satiety [38–43, 70]. Nevertheless, CCK1 and CCK2 receptor blockade reduced alcohol drinking and anxiety during alcohol withdrawal, respectively, hinting at unique receptor-dependent central functions of CCK in regulating motivation for alcohol consumption and related emotional behaviors [12, 77, 78]. More recently, Ballaz et al. thoroughly reviewed the hypothesis that endogenous CCK regulates alcohol intake, perhaps through interactions with DA, 5-HT, and endogenous opioid systems [3].

CCK neurocircuitry and neurotechnology

As described, early studies on CCK in addiction implicated sources of CCK in the ventral striatum, as well as NAcc-projecting VTA neurons that co-express CCK and DA, leading to multiple possibilities for CCK and DA interactions in modulating DA release and drug reward. Beyond these midbrain sites, recent investigations identified addiction-relevant functions of CCK throughout the basolateral amygdala (BLA) and extended amygdala (e.g., BNST). For example, multiple CCK neuronal subtypes exist in the BLA, including CCK + GABAergic interneurons that express type-1 cannabinoid receptors and facilitate behavioral extinction of fear memory, suggesting their potential role in drug reward memory and sensitivity to reinforcing properties of cannabinoids [62]. Though a full discussion on the role of CCK in stress and anxiety is beyond the scope of this review, the anxiogenic role of CCK2R signaling in the BLA is likely relevant to the stress-like withdrawal symptoms following cessation of chronic exposure to drugs of abuse [61].

In the extended amygdala, a dense band of CCK neurons is localized to the medial division of the BNST and sends long-range axonal projections to the lateral hypothalamus, medial amygdala, ventral pre-mammillary nucleus, and other brain areas regulating pursuit of natural rewards like food and sex [22]. Stimulation of CCK-BNST neurons by chemogenetic or optogenetic methods was positively reinforcing in male mice, and fiber photometry recordings revealed that CCK-BNST neurons were strongly activated by cues predicting rewarding stimuli, suggesting that BNST-derived CCK may promote drug-seeking behavior in addiction [24].

In addition to VTA-DA neurons, midbrain CCK is also expressed within multiple neuronal populations of the subaqueductal paramedian zone, including the dorsal raphe nucleus (DRN) [56]. Unlike archetypal 5HT cells of the DRN, single-cell RNA sequencing (sc-RNAseq) experiments indicated that CCK is expressed preferentially among DA-synthesizing neurons in the ventral periaqueductal gray that have been assigned to the DRN [35]. In other words, results from investigations of CCK-DA interactions throughout the classical mesolimbic pathway in addiction may also correspond to CCK-DA interactions through non-canonical pathways of DA DRN neurons that project to the VTA, hypothalamus, amygdala, and BNST [9].
In close proximity to the DRN, CCK is expressed in a separate midline group of peptidergic neurons called the centrally projecting Edinger-Westphal nucleus (EWcp) [57, 58, 71]. EWcp neurons are strongly activated by alcohol drinking and psychostimulants [23, 63, 64, 67], and expression of EWcp neuropeptides (including CCK at both the mRNA and protein levels) corresponds with the degree of voluntary alcohol intake among inbred mouse strains [20, 21, 25].

Altogether, the unique expression patterns of CCK in reward-promoting and alcohol-activated neurons of the BLA, BNST, DRN, and EWcp highlight the need for detailed investigations of the release and signaling mechanisms of CCK in these circuits to understand how this neuropeptide may be controlling discrete addiction-related behavioral processes (Fig. 1).

With this in mind, knowledge on the mechanisms regulating CCK release and signaling is limited. In mammals, release of neuropeptides have mostly been studied in the neurohypophysis, where large terminals contain high amounts of oxytocin or vasopressin large dense core vesicles (DCVs). Similarly, magnocellular neurons in the hypothalamus loaded with oxytocin DCVs have been a model system for understanding somatodendritic release of neuropeptides [73]. As vesicles containing other neuropeptides like CCK are typically smaller in size and number, it remains to be explored whether CCK shares similar release mechanisms. Spurred by the difficulty of measuring neuropeptide concentrations in vivo, recent breakthroughs in protein engineering have produced fluorescent receptor sensors that rely on dynamic green fluorescent protein (GFP) signals to report neuropeptide binding and receptor signaling with unprecedented specificity and temporal resolution [1, 69, 85]. Using cell-specific viral approaches, targeting these neuropeptide sensors to defined neural pathways may profoundly alter the ability of scientists to detect and measure functional actions of peptides in behavioral animal models of addiction [27, 52, 66].

**Summary and conclusions**

Accumulating evidence over the past three decades suggest that the CCK system underlies a variety of behaviors related to substance use disorders. CCK actions across subcortical circuits are likely critical for emotional and reward-seeking aspects of addiction, with differential contributions of neuronal populations across the striatum, amygdala, and midbrain. The multifold nature of the endogenous CCK system and its role in addiction arise from gene polymorphism, peptide synthesis and post-translational processing, release modes, receptor subtypes with various signaling pathways, localization in terms of cell types and regions, and interaction with other neurotransmitter/neuromodulator systems. Given its wide distribution and high versatility, CCK is a promising candidate for unraveling the sex differences and hormonal influences on addictive behaviors. The challenges to detect CCK at physiological conditions have impeded the detailed investigation of CCK in addiction, but recent advances in neurotechnology offer genetic and optical methods complementary to traditional pharmacology. In conclusion, future studies with these sensitive and specific tools will provide novel insights of CCK and addiction at a high level of granularity.
Acknowledgements

This work supported by NIH R00 AA025677 (W.J.G.), a Stanford Psychiatry Innovator Grant (W.J.G.) and a seed grant from the Stanford Center for Women’s Health and Sex Differences in Medicine (W.J.G). We thank Julie A. Kauer, Matthew B. Pomrenze, Valentina Martinez-Damonte, Daniel W. Bayless, Joseph R. Knoedler, and Andrey E. Ryabinin for insightful discussions.

Abbreviations:

| Abbreviation | Description |
|--------------|-------------|
| BLA          | Basolateral amygdala |
| BNST         | Bed nucleus of stria terminalis |
| CCK          | Cholecystokinin |
| DA           | Dopamine |
| DCVs         | Dense core vesicles |
| DRN          | Dorsal raphe nucleus |
| EWcp         | Centrally projecting Edinger-Westphal nucleus |
| E2           | Estradiol |
| GABA         | Gamma-aminobutyric acid |
| mRNA         | Messenger ribonucleic acid |
| NAcc         | Nucleus accumbens |
| 5-HT         | Serotonin |
| VTA          | Ventral tegmental area |

References

[1]. Abraham AD, Casello SM, Schattauer SS, Wong BA, Mizuno GO, Mahe K, Tian L, Land BB, Chavkin C, Release of endogenous dynorphin opioids in the prefrontal cortex disrupts cognition, Neuropsychopharmacology 46 (2021) 2330–2339. [PubMed: 34545197]
[2]. Ballaz S, The unappreciated roles of the cholecystokinin receptor CCK(1) in brain functioning, Rev. Neurosci 28 (2017) 573–585. [PubMed: 28343167]
[3]. Ballaz S, Espinosa N, Bourin M, Does endogenous cholecystokinin modulate alcohol intake? Neuropharmacology 193 (2021) 108539.
[4]. Beinfeld MC, CCK biosynthesis and processing: recent progress and future challenges, Life Sci. 61 (1997) 2359–2366. [PubMed: 9399627]
[5]. Beinfeld MC, An introduction to neuronal cholecystokinin, Peptides 22 (2001) 1197–1200. [PubMed: 11457511]
[6]. Beinfeld MC, Meyer DK, Bownstein MJ, Cholecystokinin in the central nervous system, Peptides 2 (1981) 77–79 Suppl 2. [PubMed: 6283500]
[7]. Breukel AI, Lopes da Silva FH, Ghijsen WE, Cholecystokinin (CCK-8) modulates vesicular release of excitatory amino acids in rat hippocampal nerve endings, Neurosci. Lett 234 (1997) 67–70. [PubMed: 9347948]
[8]. Bush DE, DeSousa NJ, Vaccarino FJ, Self-administration of intravenous amphetamine: effect of nucleus accumbens CCKB receptor activation on fixed-ratio responding, Psychopharmacol. (Berl.) 147 (1999) 331–334.

[9]. Cardozo Pinto DF, Yang H, Pollak Dorocic I, de Jong JW, Han VJ, Peck JR, Zhu Y, Liu C, Beier KT, Smidt MP, et al., Characterization of transgenic mouse models targeting neuromodulatory systems reveals organizational principles of the dorsal raphe, Nat. Commun 10 (2019) 4633. [PubMed: 31604921]

[10]. Chung L, Moore SD, Cox CL, Cholecystokinin action on layer 6b neurons in somatosensory cortex, Brain Res. 1282 (2009) 10–19. [PubMed: 19497313]

[11]. Crawley JN, Corwin RL, Biological actions of cholecystokinin, Peptides 15 (1994) 731–755. [PubMed: 7937354]

[12]. Crespi F, Corsi M, England T, Ratti E, Trist DG, Gaviraghi G, Spontaneous preference for ethanol in naive rats is influenced by cholecystokinin A receptor antagonism, Alcohol 14 (1997) 327–332. [PubMed: 9209547]

[13]. Crespi F, Corsi M, Reggiani A, Ratti E, Gaviraghi G, Involvement of cholecystokinin within craving for cocaine: role of cholecystokinin receptor ligands, Expert Opin. Investig. Drugs 9 (2000) 2249–2258.

[14]. Deng PY, Xiao Z, Jha A, Ramonet D, Matsui T, Leitges M, Shin HS, Porter JE, Geiger JD, Lei S, Cholecystokinin facilitates glutamate release by increasing the number of readily releasable vesicles and releasing probability, J. Neurosci 30 (2010) 5136–5148. [PubMed: 20392936]

[15]. Deschodt-Lanckman M, Bui ND, Koulischer D, Paroutaud P, Strosberg AD, Cholecystokinin octa- and tetrapeptide degradation by synaptic membranes. II. Solubilization and separation of membrane-bound CCK-8 cleaving enzymes, Peptides 4 (1983) 71–78. [PubMed: 6306618]

[16]. DeSousa NJ, Wunderlich GR, De Cabo C, Vaccarino FJ, The expression of behavioral sensitization to amphetamine: role of CCK(A) receptors, Pharmcol. Biochem. Behav 62 (1999) 31–37. [PubMed: 9972842]

[17]. Eckersell CB, Micevych PE, Opiate receptors modulate estrogen-induced cholecystokinin and tachykinin but not enkephalin messenger RNA levels in the limbic system and hypothalamus, Neuroscience 80 (1997) 473–485. [PubMed: 9284350]

[18]. Elkashef A Jr, Brasic JR, Cantelina LR, Kahn R, Chiang N, Ye W, Zhou Y, Mojsiak J, Warren KR, Crabb A, et al., A cholecystokinin B receptor antagonist and cocaine interaction, phase I study, CNS Neurosci. Ther 25 (2019) 136–146. [PubMed: 29923314]

[19]. Feifel D, Shilling PD, Kuczenski R, Segal DS, Altered extracellular dopamine concentration in the brains of cholecystokinin-a receptor deficient rats, Neurosci. Lett 348 (2003) 147–150. [PubMed: 12932815]

[20]. Giardino WJ, Cocking DL, Kaur S, Cunningham CL, Ryabinin AE, Urocortin-1 within the centrally-projecting Edinger-Westphal nucleus is critical for ethanol preference, PLoS One 6 (2011) e26997.

[21]. Giardino WJ, Cote DM, Li J, Ryabinin AE, Characterization of genetic differences within the centrally projecting edinger-westphal nucleus of C57BL/6J and DBA/2J mice by expression profiling, Front. Neuroanat 6 (2012) 5. [PubMed: 22347848]

[22]. Giardino WJ, Ehan-Rothschild A, Christoffel DJ, Li SB, Malenka RC, de Lecea L, Parallel circuits from the bed nuclei of stria terminalis to the lateral hypothalamus drive opposing emotional states, Nat. Neurosci 21 (2018) 1084–1095. [PubMed: 30038273]

[23]. Giardino WJ, Pastor R, Anacker AM, Spangler E, Cote DM, Li J, Stenzel-Poore MP, Phillips TJ, Ryabinin AE, Dissection of corticotropin-releasing factor system involvement in locomotor sensitivity to methamphetamine, Genes Brain Behav. 10 (2011) 78–89. [PubMed: 20731720]

[24]. Giardino WJ, Pomrenze MB, Extended amygdala neuropeptide circuitry of emotional arousal: waking up on the wrong side of the bed nuclei of STRIA terminalis, Front. Behav. Neurosci 15 (2021) 613025.

[25]. Giardino WJ, Rodriguez ED, Smith ML, Ford MM, Galili D, Mitchell SH, Chen A, Ryabinin AE, Control of chronic excessive alcohol drinking by genetic manipulation of the Edinger-Westphal nucleus urocortin-1 neuropeptide system, Transl. Psychiatry 7 (2017) e1021. [PubMed: 28140406]
[26]. Gou H, Wen D, Ma C, Li M, Li Y, Zhang W, Liu L, Cong B, Protective effects of cholecystokinin-8 on methamphetamine-induced behavioral changes and dopaminergic neurodegeneration in mice, Behav. Brain Res 283 (2015) 87–96. [PubMed: 25629941]

[27]. Guillaumin MCC, Burdakov D, Neuropeptides as primary mediators of brain circuit connectivity, Front. Neurosci 15 (2021) 644313.

[28]. Hebb AL, Poulin JF, Roach SP, Zacharko RM, Drolet G, Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion, Prog. Neuropsychopharmacol. Biol. Psychiatry 29 (2005) 1225–1238. [PubMed: 16242828]

[29]. Higgins GA, Joharchi N, Wang Y, Corrigall WA, Sellers EM, The CCKA receptor antagonist devazepide does not modify opioid self-administration or drug discrimination: comparison with the dopamine antagonist haloperidol, Brain Res. 640 (1994) 246–254. [PubMed: 8004452]

[30]. Higgins GA, Nguyen P, Sellers EM, Blockade of morphine place conditioning by the CCKA receptor antagonist devazepide, Eur. J. Pharmacol 197 (1991) 229–230. [PubMed: 1915570]

[31]. Higgins GA, Nguyen P, Sellers EM, Morphine place conditioning is differentially affected by CCKA and CCKB receptor antagonists, Brain Res. 572 (1992) 208–215. [PubMed: 1611514]

[32]. Higgins GA, Sils TL, Tomkins DM, Sellers EM, Vaccarino FJ, Evidence for the contribution of CCKB receptor mechanisms to individual differences in amphetamine-induced locomotion, Pharmacol. Biochem. Behav 48 (1994) 1019–1024. [PubMed: 7972279]

[33]. Hill DR, Shaw TM, Dourish CT, Woodruff GN, CCK-A receptors in the rat interpeduncular nucleus: evidence for a presynaptic location, Brain Res. 454 (1988) 101–105. [PubMed: 3408996]

[34]. Hokfelt T, Herrera-Marschitz M, Seroogy K, Ju G, Staines WA, Holets V, Schalling M, Ungerstedt U, Rehfeld JF, et al., Immunohistochemical studies on cholecystokinin (CCK)-immunoreactive neurons in the rat using sequence specific antisera and with special reference to the caudate nucleus and primary sensory neurons, J. Chem. Neuroanat 1 (1988) 11–51. [PubMed: 3077312]

[35]. Huang KW, Ochandarena NE, Philson AC, Hyun M, Birnbaum JE, Cicconet M, Sabatini BL, Molecular and anatomical organization of the dorsal raphe nucleus, Elife 8 (2019) e46464.

[36]. Hurd YL, Lindefors N, Brodin E, Brene S, Persson H, Ungerstedt U, Hokfelt T, Amphetamine regulation of mesolimbic dopamine/cholecystokinin neurotransmission, Brain Res. 578 (1992) 317–326. [PubMed: 1354999]

[37]. Kawaguchi Y, Kondo S, Parvalbumin, somatostatin and cholecystokinin as chemical markers for specific GABAergic interneuron types in the rat frontal cortex, J. Neurocytol 31 (2002) 277–287. [PubMed: 12815247]

[38]. Kulkosky PJ, Effect of cholecystokinin octapeptide on ethanol intake in the rat, Alcohol 1 (1984) 125–128. [PubMed: 6100356]

[39]. Kulkosky PJ, Chavez MR, Sulphated cholecystokinin octapeptide inhibits ethanol consumption in the rat, Alcohol 1 (1984) 409–412. [PubMed: 6100357]

[40]. Kulkosky PJ, Clayborne YJ, Sandoval SL, Cholecystokinin and Bombesin inhibit ethanol and food intake in rats selectively bred for ethanol sensitivity, Alcohol Clin. Exp. Res 17 (1993) 545–551. [PubMed: 8333582]

[41]. Kulkosky PJ, Foderaro MA, Sandoval SL, Cesar SS, Marrinan DA, Cholecystokinin-induced satiation with ethanol: effects of lighting cycle and limited access procedures, Alcohol 8 (1991) 223–227. [PubMed: 2069737]

[42]. Kulkosky PJ, Glazner GW, Dose-additive inhibition of intake of ethanol by cholecystokinin and Bombesin, Alcohol Clin. Exp. Res 12 (1988) 277–281. [PubMed: 3287991]

[43]. Kulkosky PJ, Sanchez MR, Foderaro MA, Chiu N, Cholecystokinin and satiation with alcohol, Alcohol 6 (1989) 395–402. [PubMed: 2818843]

[44]. Lee SY, Soltesz I, Cholecystokinin: a multi-functional molecular switch of neuronal circuits, Dev. Neurobiol 71 (2011) 83–91. [PubMed: 21154912]

[45]. Liu Q, Yang D, Zhuang Y, Croll TI, Cai X, Dai A, He X, Duan J, Yin W, Ye C, et al., Ligand recognition and G-protein coupling selectivity of cholecystokinin a receptor, Nat. Chem. Biol 17 (2021) 1238–1244. [PubMed: 34556862]
[46]. Loonam TM, Noailles PA, Yu J, Zhu JP, Angulo JA, Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum, Life Sci. 73 (2003) 727–739. [PubMed: 12801594]

[47]. Lu L, Zhang B, Liu Z, Zhang Z, Reactivation of cocaine conditioned place preference induced by stress is reversed by cholecystokinin-B receptors antagonist in rats, Brain Res. 954 (2002) 132–140. [PubMed: 12393241]

[48]. Lucas LR, Angulo JA, Le Moal M, McEwen BS, Piazza PV, Neurochemical characterization of individual vulnerability to addictive drugs in rats, Eur. J. Neurosci 10 (1998) 3153–3163. [PubMed: 9786209]

[49]. Martin TA, Jayanthi S, McCoy MT, Brannock C, Ladenheim B, Garrett T, Lehmann E, Becker KG, Cadet JL, Methamphetamine causes differential alterations in gene expression and patterns of histone acetylation/hypoacetylation in the rat nucleus accumbens, PLoS One 7 (2012) e34236.

[50]. Micevych PE, Eckerseil CB, Brecha N, Holland KL, Estrogen modulation of opioid and cholecystokinin systems in the limbic-hypothalamic circuit, Brain Res. Bull 44 (1997) 335–343. [PubMed: 9370197]

[51]. Moran TH, Schwartz GJ, Neurobiology of cholecystokinin, Crit. Rev. Neurobiol 9 (1994) 1–28. [PubMed: 8828002]

[52]. Nectow AR, Nestler EJ, Viral tools for neuroscience, Nat. Rev. Neurosci 21 (2020) 669–681. [PubMed: 33110222]

[53]. Noble F, Benturquia N, Crete D, Canestrelli C, Mas Nieto M, Wilson J, Roques BP, Relationship between vulnerability to reinforcing effects of morphine and activity of the endogenous cholecystokinin system in Lewis and Fischer rats, Addict. Biol 17 (2012) 528–538. [PubMed: 21309946]

[54]. Park HM, Satta R, Davis RG, Goo YA, LeDuc RD, Fellers RT, Greer JB, Romanova EV, Rubakhin SS, Tai R, et al., Multidimensional top-down proteomics of brain-region-specific mouse brain proteomes responsive to cocaine and estradiol, J. Proteome Res 18 (2019) 3999–4012. [PubMed: 31550894]

[55]. Pommer B, Beslot F, Simon A, Pophillat M, Matsui T, Dauge V, Roques BP, Noble F, Deletion of CCK2 receptor in mice results in an upregulation of the endogenous opioid system, J. Neurosci 22 (2002) 2005–2011. [PubMed: 11880531]

[56]. Pomrenze MB, Walker LC, Giardino WJ, Gray areas: neuropeptide circuits linking the Edinger-Westphal and dorsal raphe nuclei in addiction, Neuropsychopharmacology 198 (2021) 108769.

[57]. Priest MF, Freda SN, Badong D, Dumrongprechachan V, Kozorovitskiy Y, Peptidergic modulation of fear responses by the Edinger-Westphal nucleus, bioRxiv (2021). https://www.biorxiv.org/content/10.1101/2021.08.05.455317v1.

[58]. Rattray M, Savery D, Wotherspoon G, Priestley JV, Smith GS, Two populations of cells that express preprocholecystokinin mRNA in ventral periaqueductal grey, Neurosci. Lett 143 (1992) 55–59. [PubMed: 1436682]

[59]. Rehfeld JF, Friis-Hansen L, Goetze JP, Hansen TV, The biology of cholecystokinin and gastrin peptides, Curr. Top. Med. Chem 7 (2007) 1154–1165. [PubMed: 17584137]

[60]. Rose C, Vargas F, Facchinetti P, Bourgeat P, Bambal RB, Bishop PB, Chan SM, Moore AN, Ganellin CR, Schwartz JC, Characterization and inhibition of a cholecystokinin-inactivating serine peptidase, Nature 380 (1996) 403–409. [PubMed: 8602240]

[61]. Rotzinger S, Vaccarino FJ, Cholecystokinin receptor subtypes: role in the modulation of anxiety-related and reward-related behaviours in animal models, J. Psychiatry Neurosci 28 (2003) 171–181. [PubMed: 12790157]

[62]. Rovira-Esteban L, Gunduz-Cinar O, Bukalo O, Limoges A, Brockway E, Muller K, Fenn L, Kim YS, Ramakrishnan C, Andrasi T, et al., Excitation of diverse classes of cholecystokinin interneurons in the basal amygdala facilitates fear extinction, eNeuro 6 (6) (2019) ENEURO.0220–19.2019.

[63]. Ryabinin AE, Giardino WJ, Contribution of Urocortin to the development of excessive drinking, Int. Rev. Neurobiol 136 (2017) 275–291. [PubMed: 29056154]
[64]. Ryabinin AE, Tsoory MM, Kozicz T, Thiele TE, Neufeld-Cohen A, Chen A, Lowery-Gionta EG, Giardino WJ, Kaur S, Urocortins: cRF’s siblings and their potential role in anxiety, depression and alcohol drinking behavior, Alcohol 46 (2012) 349–357. [PubMed: 22444954]

[65]. Saleh TM, Kombian SB, Zidichouski JA, Pittman QJ, Cholecystokinin and neurotensin inversely modulate excitatory synaptic transmission in the parabrachial nucleus in vitro, Neuroscience 77 (1997) 23–35. [PubMed: 9044371]

[66]. Saunders BT, Richard JM, Janak PH, Contemporary approaches to neural circuit manipulation and mapping: focus on reward and addiction, Philos. Trans. R. Soc. Lond. B Biol. Sci 370 (2015) 20140210.

[67]. Schank JR, Ryabinin AE, Giardino WJ, Ciccocioppo R, Heilig M, Stress-related neuropeptides and addictive behaviors: beyond the usual suspects, Neuron 76 (2012) 192–208. [PubMed: 23040815]

[68]. Sugeta S, Hirai Y, Maezawa H, Inoue N, Yamazaki Y, Funahashi M, Presynaptically mediated effects of cholecystokinin-8 on the excitability of area postrema neurons in rat brain slices, Brain Res. 1618 (2015) 83–90. [PubMed: 26005131]

[69]. Sun F, Zhou J, Dai B, Qian T, Zeng J, Li X, Zhuo Y, Zhang Y, Wang Y, Qian C, et al., Next-generation GRAB sensors for monitoring dopaminergic activity in vivo, Nat. Methods 17 (2020) 1156–1166. [PubMed: 33087905]

[70]. Thiele TE, Stewart RB, Badia-Elder NE, Geary N, Massi M, Leibowitz SF, Hoebel BG, Egli M, Overlapping peptide control of alcohol self-administration and feeding, Alcohol. Clin. Exp. Res 28 (2004) 288–294. [PubMed: 15112936]

[71]. Topilko T, D. SL Pacheco D, Verny F, Deleuze C, Gaspar P, Renier N, Midbrain Peptidergic Neurons Enable Maternal Nesting, Neuron 110 (8) (2022) 1385–1399 e8. [PubMed: 35123655]

[72]. Vaccarino FJ, Nucleus accumbens dopamine-CCK interactions in psychostimulant reward and related behaviors, Neurosci. Biobehav. Rev 18 (1994) 207–214. [PubMed: 7914685]

[73]. Van den Pol AN, Neuropeptide transmission in brain circuits, Neuron 76 (2012) 98–115. [PubMed: 23040809]

[74]. Wen D, Cong B, Ma C, Yang S, Yu H, Ni Z, Li S, The effects of exogenous CCK-8 on the acquisition and expression of morphine-induced CPP, Neurosci. Lett 510 (2012) 24–28. [PubMed: 22245440]

[75]. Wen D, Sun D, Zang G, Hao L, Liu X, Yu F, Ma C, Cong B, Cholecystokinin octapeptide induces endogenous opioid-dependent anxiolytic effects in morphine-withdrawal rats, Neuroscience 277 (2014) 14–25. [PubMed: 24993476]

[76]. Wen D, Zang G, Sun D, Yu F, Mei D, Ma C, Cong B, Cholecystokin-octapeptide restored morphine-induced hippocampal long-term potentiation impairment in rats, Neurosci. Lett 559 (2014) 76–81. [PubMed: 24309294]

[77]. Wilson J, Little HJ, CCK(B) antagonists protect against some aspects of the ethanol withdrawal syndrome, Pharmacol. Biochem. Behav 59 (1998) 967–973. [PubMed: 9586857]

[78]. Wilson J, Watson WP, Little HJ, CCK(B) antagonists protect against anxiety-related behaviour produced by ethanol withdrawal, measured using the elevated plus maze, Psychopharmacol. (Berl.) 137 (1998) 120–131.

[79]. Wunderlich GR, Rotzinger S, Bush DE, DeSousa NJ, Vaccarino FJ, Cholecystokinin modulation of locomotor behavior in rats is sensitized by chronic amphetamine and chronic restraint stress exposure, Brain Res. 1001 (2004) 95–107. [PubMed: 14972658]

[80]. You ZB, Herrera-Marschitz M, Brodin E, Meana JJ, Morino P, Hokfelt T, Silveira R, Goiny M, Ungerstedt U, On the origin of striatal cholecystokinin release: studies with in vivo microdialysis, J. Neurochem 62 (1994) 76–85. [PubMed: 7903356]

[81]. Yu H, Wen D, Ma C, Meng Y, Li S, Ni Z, Cong B, Effects of exogenous cholecystokinin octapeptide on acquisition of naloxone precipitated withdrawal induced conditioned place aversion in rats, PLoS One 7 (2012) e41860.

[82]. Zaborszky L, Alheid GF, Beinfeld MC, Eiden LE, Heimer L, Palkovits M, Cholecystokinin innervation of the ventral striatum: a morphological and radioimmunological study, Neuroscience 14 (1985) 427–453. [PubMed: 3887206]
[83]. Zhang X, He C, Wang M, Zhou Q, Yang D, Zhu Y, Feng W, Zhang H, Dai A, Chu X, et al., Structures of the human cholecystokinin receptors bound to agonists and antagonists, Nat. Chem. Biol 17 (2021) 1230–1237. [PubMed: 34556863]

[84]. Zuzel KA, Rose C, Schwartz JC, Assessment of the role of “enkephalinase” in cholecystokinin inactivation, Neuroscience 15 (1985) 149–158. [PubMed: 3892359]

[85]. Wang H, Qian T, Zhao Y, Zhuo Y, Wu C, Osakada T, Chen P, Ren H, Yan Y, Geng L, et al., A toolkit of highly selective and sensitive genetically encoded neuropeptide sensors. bioRxiv. doi: 10.1101/2022.03.26.485911v1.
Fig. 1.
Depiction of CCK-containing neuronal cell bodies, as well as axonal projections and sites of CCK receptor signaling hypothesized to contribute to addiction to psychostimulants, opioids, and alcohol. Key subcortical regions are color-coded to show co-expressed neurotransmitters and neuromodulators. Other brain regions with known CCK function are labeled in gray. CRF, corticotropin-releasing factor; NTS, nucleus of the solitary tract; ORX, orexin; PFC, prefrontal cortex; Ucn1, urocortin-1. Created with BioRender.com.
Table 1

Summary of behavioral effects or molecular changes by altering CCK pathways in animal models of psychostimulant abuse. AMP, amphetamine; METH, methamphetamine; TH, tyrosine hydroxylase; DAT, dopamine transporter; CPu, caudate putamen; SN, substantia nigra; CPP, conditioned place preference.

| Manipulation of CCK/CCKR | Brain Region | Molecular/Behavioral Effect | Animal Model | Refs. |
|--------------------------|--------------|-----------------------------|--------------|-------|
| CCK1/2R agonist (CCK-8)  | n/a (i.c.v.)  | • Attenuated METH-induced TH & DAT reduction in striatum/TH reduction in SN  
• Attenuated METH-induced hyper-locomotion, behavioral sensitization, and hyperthermia |♂ C57BL/6 mice | [26] |
| CCK1R deficient          | NAcc, CPu    | • Higher baseline DA in CPu  
• Greater DA response in NAc to cocaine & AMP | OLETF rats | [19] |
| CCK1R antagonist (devazepide) | n/a (i.p.) | Blocked AMP-sensitized locomotion in high responders pre-exposed to AMP |♂ Wistar rats | [16] |
| CCK1R antagonist (devazepide) | n/a (s.c.) | No effect on high responders |♂ Sprague-Dawley rats | [47] |
| CCK1R antagonist (PD-140,548) | NAcc | Inhibited cocaine-induced reinstatement of cocaine CPP |♂ Wistar rats | [79] |
| CCK2R agonist (CCK-5) | n/a (i.p.) | Increased locomotor sensitization |♂ WP (water preferred) Wistar rats | [12] |
| CCK2R agonist (CCK-5) | NAcc | Increased AMP self-administration |♂ Wistar rats | [8] |
| CCK2R antagonist (LV-150,013) | n/a (i.p.) | Reduced cocaine consumption |♂ CD (cocaine drinking) Wistar rats | [13] |
| CCK2R antagonist (L-365,260) | n/a (s.c.) | Potentiates AMP-induced hyper-locomotion in low responders |♂ Wistar rats | [30] |
| CCK2R antagonist (L-365,260) | NAcc, Amygdala | Inhibited stress-induced reinstatement of cocaine CPP |♂ Sprague-Dawley rats | [47] |
| CCK2R antagonist (L-369,293) | CPu | Greater DA response in CPu to cocaine |♂ Sprague-Dawley rats | [46] |
### Table 2

Summary of behavioral effects or molecular changes by altering CCK pathways in animal models of opioid abuse.

| Manipulation of CCK/CCKR | Brain Region | Molecular/Behavioral Effect                                                                 | Animal Model | Refs. |
|--------------------------|--------------|-------------------------------------------------------------------------------------------|--------------|-------|
| CCK1/2R agonist (CCK-8)  | n/a (i.c.v.) | Blocked morphine CPP; attenuated CPP extinction, reduced locomotion                      | ♂ Wistar rats | [74]  |
|                          |              | • Inhibited anxiety-like behavior during morphine withdrawal                              |              |       |
|                          |              | • Effect can be inhibited by CCK1R antagonist (devazepide) & μ-opioid receptor antagonist (CTAP) |              |       |
| CCK1/2R agonist (CCK-8)  |              | Restored morphine-induced LTP reduction in dentate gyrus                                  |              | [81]  |
|                          |              | • Effect can be inhibited by CCK2R antagonist (L-365,260)                                  |              |       |
| CCK1R antagonist(devazepide) | n/a (s.c.) | Blocked morphine CPP                                                                     | ♂ Wistar rats | [30]  |
| CCK2R agonist (BC264)   | NAcc         | Blocked morphine CPP                                                                     | ♂ Lewis rats  | [53]  |
| CCK2R deletion          | n/a          | • Increased cAMP production induced by μ-opioid, δ-opioid, and D2 agonists                | C57BL/6 J mice | [55]  |
|                          |              | • Hyperlocomotion at baseline and with morphine, more severe withdrawal signs              |              |       |
| CCK2R antagonist (L-365,260) | n/a (s.c.) | Potentiated low dose morphine CPP                                                        | ♂ Wistar rats | [31]  |
| CCK2R antagonist (PD-134,308) | NAcc       | Potentiated low dose morphine CPP                                                        | ♂ Fisher rats | [53]  |